Literature DB >> 26374752

Routine endoscopic ultrasound in moderate and indeterminate risk patients of suspected choledocholithiasis to avoid unwarranted ERCP: A prospective randomized blinded study.

Rajesh Sharma1,2, John Menachery3, Narendra S Choudhary3, Mandhir Kumar3, Rajesh Puri4, Randhir Sud3.   

Abstract

BACKGROUND: Endoscopic ultrasound (EUS) is the most sensitive test for diagnosis of common bile duct stones and it may avoid unnecessary endoscopic retrograde cholangiopancreatography (ERCP). AIM: The purpose of this study was to evaluate whether EUS done initially would avoid unnecessary ERCP in patients with moderate or indeterminate risk for occurrence of choledocholithiasis.
METHODS: Patients with biliary colic or acute biliary pancreatitis, who were referred for suspected choledocholithiasis on the basis of alterations in liver function tests were prospectively included over 12 months period in blinded randomized fashion. Endoscopic ultrasonography was performed for all patients. Patients were randomized to two groups. ERCP was done in all patients in group A irrespective of the EUS findings, while in the group B, ERCP was done only in those patients in whom EUS was suggested the presence of common bile duct stone or sludge.
RESULTS: A total of 50 patients were randomized into each group. EUS diagnosed common bile duct stones in 24 out of 50 patients (48 %) in group A, and ERCP identified common bile duct stones in 23 of those 24 patients. Twenty-eight out of 50 patients had common bile duct stones/sludge in group B, which were removed by subsequent ERCP. However, ERCP could be avoided in 22 cases (44 %) of group B and none of these patients had biliary symptoms up to 6 months of follow up.
CONCLUSION: In patients with moderate or indeterminate risk for choledocholithiasis, prior EUS done for confirmation of choledocholithiasis avoids unnecessary ERCP in almost half of the cases.

Entities:  

Keywords:  Choledocholithiasis; Common bile duct; ERCP; Endoscopic ultrasound

Mesh:

Year:  2015        PMID: 26374752     DOI: 10.1007/s12664-015-0581-4

Source DB:  PubMed          Journal:  Indian J Gastroenterol        ISSN: 0254-8860


  16 in total

1.  Complications of diagnostic and therapeutic ERCP: a prospective multicenter study.

Authors:  E Masci; G Toti; A Mariani; S Curioni; A Lomazzi; M Dinelli; G Minoli; C Crosta; U Comin; A Fertitta; A Prada; G R Passoni; P A Testoni
Journal:  Am J Gastroenterol       Date:  2001-02       Impact factor: 10.864

Review 2.  Systematic review of endoscopic ultrasonography versus endoscopic retrograde cholangiopancreatography for suspected choledocholithiasis.

Authors:  M S Petrov; T J Savides
Journal:  Br J Surg       Date:  2009-09       Impact factor: 6.939

3.  EUS-guided ERCP for patients with intermediate probability for choledocholithiasis: is it time for all of us to start doing this?

Authors:  Thomas J Savides
Journal:  Gastrointest Endosc       Date:  2008-04       Impact factor: 9.427

4.  Major early complications from diagnostic and therapeutic ERCP: a prospective multicenter study.

Authors:  S Loperfido; G Angelini; G Benedetti; F Chilovi; F Costan; F De Berardinis; M De Bernardin; A Ederle; P Fina; A Fratton
Journal:  Gastrointest Endosc       Date:  1998-07       Impact factor: 9.427

5.  Indications, contraindications, and complications of endoscopic ultrasonography.

Authors:  C J Lightdale
Journal:  Gastrointest Endosc       Date:  1996-02       Impact factor: 9.427

6.  Endoscopic ultrasonography versus cholangiography for the diagnosis of choledocholithiasis.

Authors:  M I Canto; A Chak; T Stellato; M V Sivak
Journal:  Gastrointest Endosc       Date:  1998-06       Impact factor: 9.427

7.  Prospective controlled study of endoscopic ultrasonography and endoscopic retrograde cholangiography in patients with suspected common-bileduct lithiasis.

Authors:  F Prat; G Amouyal; P Amouyal; G Pelletier; J Fritsch; A D Choury; C Buffet; J P Etienne
Journal:  Lancet       Date:  1996-01-13       Impact factor: 79.321

8.  EUS versus endoscopic retrograde cholangiography for patients with intermediate probability of bile duct stones: a prospective randomized trial.

Authors:  Tarkan Karakan; Mehmet Cindoruk; Hakan Alagozlu; Meltem Ergun; Sukru Dumlu; Selahattin Unal
Journal:  Gastrointest Endosc       Date:  2008-11-18       Impact factor: 9.427

9.  EUS: a meta-analysis of test performance in suspected choledocholithiasis.

Authors:  Frances Tse; Louis Liu; Alan N Barkun; David Armstrong; Paul Moayyedi
Journal:  Gastrointest Endosc       Date:  2008-02       Impact factor: 9.427

10.  Endoscopic ultrasound versus endoscopic retrograde cholangiography for patients with intermediate probability of bile duct stones: a randomized trial comparing two management strategies.

Authors:  M Polkowski; J Regula; A Tilszer; E Butruk
Journal:  Endoscopy       Date:  2007-04       Impact factor: 10.093

View more
  5 in total

1.  Dynamic liver test patterns do not predict bile duct stones.

Authors:  Chung Yao Yu; Nitzan Roth; Niraj Jani; Jaehoon Cho; Jacques Van Dam; Rick Selby; James Buxbaum
Journal:  Surg Endosc       Date:  2019-03-25       Impact factor: 4.584

2.  Nonradiation, Endoscopic Ultrasound-Based Endoscopic Retrograde Cholangiopancreatography.

Authors:  Kenneth F Binmoeller
Journal:  Gastroenterol Hepatol (N Y)       Date:  2017-01

3.  Routine endoscopic ultrasound in moderate and indeterminate risk patients of suspected choledocholithiasis to avoid unwarranted ERCP: A prospective randomized blinded study.

Authors:  Supriyo Ghatak; Sumit Gulati
Journal:  Indian J Gastroenterol       Date:  2016-07-26

4.  Endoscopic ultrasonography versus magnetic resonance cholangiopancreatography for suspected choledocholithiasis: Comments from the radiologists'.

Authors:  Sheng Pan; Qiyong Guo
Journal:  Endosc Ultrasound       Date:  2016 Mar-Apr       Impact factor: 5.628

5.  Optimal Evaluation of Suspected Choledocholithiasis: Does This Patient Really Have Choledocholithiasis?

Authors:  Tae Yoon Lee
Journal:  Clin Endosc       Date:  2017-09-29
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.